Immunomodulation by thalidomide and thalidomide analogues.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Who cites it

52 citing papers in PubMed.

1. Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.Leukemia & lymphoma · 2010
   Trial
2. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008
   Trial
3. Microglia depletion improves hippocampal circuit function after mild traumatic brain injury in male mice.Brain, behavior, and immunity · 2026
   Article
4. The cyclimids: Degron-inspired cereblon binders for targeted protein degradation.Cell chemical biology · 2024
   Article
5. Repurposing of thalidomide and its derivatives for the treatment of SARS-coV-2 infections: Hints on molecular action.British journal of clinical pharmacology · 2021
   Article
6. Repurposing approved drugs for cancer therapy.British medical bulletin · 2021
   Review
7. Hypnotic effect of thalidomide is independent of teratogenic ubiquitin/proteasome pathway.Proceedings of the National Academy of Sciences of the United States of America · 2020
   Article
8. Immunotherapy in Multiple Myeloma.Cells · 2020
   Review
9. Repurposing approved drugs on the pathway to novel therapies.Medicinal research reviews · 2020
   Review
10. Thalidomide and Phosphodiesterase 4 Inhibitors as Host Directed Therapeutics for Tuberculous Meningitis: Insights From the Rabbit Model.Frontiers in cellular and infection microbiology · 2019
    Review
11. Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFCancers · 2018
    Review
12. Angiogenesis enhanced by treatment damage to hepatocellular carcinoma through the release of GDF15.Cancer medicine · 2018
    Article
13. Monocyte-Derived Dendritic Cells Differentiated in the Presence of Lenalidomide Display a Semi-Mature Phenotype, Enhanced Phagocytic Capacity, and Th1 Polarization Capability.Frontiers in immunology · 2018
    Article
14. Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process.JCI insight · 2016
    Article
15. Management of Multiple Myeloma Complicated by Hepatitis C Virus Reactivation: The Role of New Antiviral Therapy.Open forum infectious diseases · 2016
    Article
16. Host-Directed Therapies for Tuberculosis.Cold Spring Harbor perspectives in medicine · 2015
    Review
17. Thalidomide-A novel therapeutic approach for pruritic papular eruption of HIV.JAAD case reports · 2015
    Article
18. Combination immune therapies to enhance anti-tumor responses by NK cells.Frontiers in immunology · 2013
    Article
19. Host-directed therapeutics for tuberculosis: can we harness the host?Microbiology and molecular biology reviews : MMBR · 2013
    Review
20. Macrophages in multiple myeloma: emerging concepts and therapeutic implications.Leukemia & lymphoma · 2013
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as